Photocure ASA

Regulatory Filings • Mar 15, 2016

Photocure announces grant of patents for Cevira®

Photocure announces grant of patents for Cevira®

Oslo, 15 March 2016 - Photocure (OSE: PHO), a specialty pharmaceutical company

with focus on photodynamic technologies in cancer and dermatology today

announces that a new patent for Cevira has been granted in Europe.

Cevira is one of Photocure's promising pipeline products and is being developed

as a new and innovative breakthrough for the treatment of precancerous lesions

of the cervix. The newly granted patent protects the Cevira drug, its use and

its combination with a drug delivery device, such as the Cevira device, until

This new key patent in Photocure's Cevira portfolio complements the company's

proprietary two European patents which protect different aspects of the Cevira

device, and which expire 2029.

Concurrently, the United States Patent and Trademark Office has issued a Notice

of Allowance for Photocure's patent application related to the Cevira drug. A US

patent protecting the Cevira drug in a similar way as the above-mentioned

European patent will issue shortly.

"The approval of this latest European patent and the Notice of Allowance for the

equivalent US application is a key milestone for us in our continued work to

secure the long-term value of Cevira. The new patents further strengthen

Photocure's robust patent portfolio and provide Cevira market exclusivity for

the long-term. Cevira is a key asset for us, with the potential to not only

treat HPV induced cervical high grade disease but also to prevent the

development of cervical cancer, which affects more than 500,000 women

annually",said Kjetil Hestdal, President and CEO of Photocure.

For further information, please contact:

Photocure

President & CEO Kjetil Hestdal

Tel: + 47 913 19 535, Email: kh@photocure.no

CFO Erik Dahl

Tel: +47 450 55 000, Email: ed@photocure.no

Notes to editors

About Photocure ASA

Photocure, headquartered in Oslo Norway, is a specialty pharmaceutical company

and world leader in photodynamic technology. Based on our unique proprietary

Photocure Technology(TM) platform, Photocure develops and commercializes highly

selective and effective solutions within disease areas with high unmet medical

need, such as bladder cancer, HPV and precancerous cervical lesions, colorectal

cancer and skin conditions. Our aim is to provide solutions which can improve

health outcomes for patients worldwide. Photocure is listed on the Oslo Stock

Exchange (OSE: PHO). Information about Photocure is available at

www.photocure.com.

This information is subject of the disclosure requirements acc. to §5-12 vphl

(Norwegian Securities Trading Act)

[HUG#1994139]